These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1674493)

  • 1. A retrospective analysis of breast cancer based on outcome differences.
    Wolman SR; Feiner HD; Schinella RA; Gimotty P; Ownby H; Maloney T; Dawson PJ
    Hum Pathol; 1991 May; 22(5):475-80. PubMed ID: 1674493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.
    Lampe B; Genz T; Maassen V; Mikorey S; Klosterhalfen T
    Arch Gynecol Obstet; 1992; 251(1):45-50. PubMed ID: 1347986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic correlates of prognosis in lymph node-positive breast carcinomas.
    Clayton F; Hopkins CL
    Cancer; 1993 Mar; 71(5):1780-90. PubMed ID: 8383579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
    Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of axillary lymph node status on the prognosis of patients with local-regional recurrence after breast-conserving surgery].
    Zhang Z; Zhang W; Li ZJ; Wang XM; Cao XC; Xiao CH
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):347-351. PubMed ID: 29860761
    [No Abstract]   [Full Text] [Related]  

  • 10. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.
    Sahin AA; Ro J; Ro JY; Blick MB; el-Naggar AK; Ordonez NG; Fritsche HA; Smith TL; Hortobagyi GN; Ayala AG
    Cancer; 1991 Aug; 68(3):549-57. PubMed ID: 1648433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
    Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
    Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S; Staff S; Tanner M; Isola J
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
    Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
    Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-erbB-2 status is an independent predictor of survival after first recurrence.
    Horiguchi J; Iino Y; Takei H; Maemura M; Takeyoshi I; Yokoe T; Ohwada S; Oyama T; Nakajima T; Morishita Y
    Int J Oncol; 1998 Jan; 12(1):123-8. PubMed ID: 9454895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma.
    Freeman JW; McGrath P; Bondada V; Selliah N; Ownby H; Maloney T; Busch RK; Busch H
    Cancer Res; 1991 Apr; 51(8):1973-8. PubMed ID: 1672621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.